180 related articles for article (PubMed ID: 9862575)
1. Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer.
Singer JM; Price P; Dale RG
Br J Cancer; 1998 Dec; 78(12):1629-33. PubMed ID: 9862575
[TBL] [Abstract][Full Text] [Related]
2. Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party.
Macbeth FR; Wheldon TE; Girling DJ; Stephens RJ; Machin D; Bleehen NM; Lamont A; Radstone DJ; Reed NS
Clin Oncol (R Coll Radiol); 1996; 8(3):176-81. PubMed ID: 8814372
[TBL] [Abstract][Full Text] [Related]
3. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.
Br J Cancer; 1991 Feb; 63(2):265-70. PubMed ID: 1705140
[TBL] [Abstract][Full Text] [Related]
4. Tumor Control Probability Analysis for Single-Fraction Carbon-Ion Radiation Therapy of Early-Stage Non-small Cell Lung Cancer.
Paz AE; Yamamoto N; Sakama M; Matsufuji N; Kanai T
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1551-1559. PubMed ID: 30076985
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
6. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
[TBL] [Abstract][Full Text] [Related]
7. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
Bentzen SM; Saunders MI; Dische S
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
[TBL] [Abstract][Full Text] [Related]
8. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
9. Predicting 2-year survival for radiation regimens in advanced non-small cell lung cancer.
Sharieff W; Okawara G; Tsakiridis T; Wright J
Clin Oncol (R Coll Radiol); 2013 Dec; 25(12):697-705. PubMed ID: 23962917
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
11. A new approach to dose escalation in non-small-cell lung cancer.
Mehta M; Scrimger R; Mackie R; Paliwal B; Chappell R; Fowler J
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):23-33. PubMed ID: 11163494
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
13. Palliative percutaneous radiotherapy in non-small-cell lung cancer.
Budach W; Belka C
Lung Cancer; 2004 Aug; 45 Suppl 2():S239-45. PubMed ID: 15552805
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
17. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
[TBL] [Abstract][Full Text] [Related]
18. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
[TBL] [Abstract][Full Text] [Related]
19. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
20. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
